Myxoid liposarcoma

6 trials 3 recruiting MedDRA PT
6 Registered trials
3 Recruiting
4 Unique sponsors
7 Unique IMPs
5 Commercial trials
Drug classes (ATC)
— ATC code not specified 5
L Oncology (ATC L) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 5 substances
Kinase inhibitor 1 substance
Vinca alkaloid 1 substance
Phase III: 2 Phase II: 2 Phase I: 1 Phase I (Other): 1

Filter these 6 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 6 trials

Phase III

2 trials
  • Intensity Therapeutics Inc. Commercial
    ERIBULIN; PAZOPANIB; TRABECTEDIN; VINBLASTINE SULFATE, CISPLATIN
    2024-512423-36-00 5 countries 2024 n=118
    Recruiting
  • Universitaet Muenster Academic
    TTF-NGR
    2024-516392-33-00 1 country 2021 n=126
    Recruiting

Phase II

2 trials
  • USWM Ct LLC Commercial
    AFAMITRESGENE AUTOLEUCEL
    2024-512847-21-00 2 countries 2019 n=48
    Ended
  • USWM Ct LLC Commercial
    LETETRESGENE AUTOLEUCEL
    2024-513032-14-00 4 countries 2020 n=21 Orphan
    Ended

Phase I

1 trial

Phase I (Other)

1 trial
  • USWM Ct LLC Commercial
    LETETRESGENE AUTOLEUCEL
    2024-513033-21-00 3 countries 2020 n=5
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
USWM Ct LLC Commercial 3 Phase I (Other), Phase II 1
Medigene AG Commercial 1 Phase I 0
Intensity Therapeutics Inc. Commercial 1 Phase III 1
Universitaet Muenster Academic 1 Phase III 1
New trials by year
2019
1
2020
2
2021
1
2024
1
← All indication landscapes